百心安-B(02185.HK):IBERIS®RDN系統產品上市會於OCC 2025會議舉行
格隆匯6月3日丨百心安-B(02185.HK)公告,由公司子公司上海安通醫療科技有限公司("安通醫療")開發的Ibers®多電極腎動脈射頻消融導管系統("Iberis®RDN系統")產品上市會於2025年5月31日在第十九屆東方心臟病學會議("OCC2025會議")期間舉行。
本次上市會由復旦大學附屬中山醫院葛均波教授、浙江大學醫學院附屬第二醫院王建安教授、上海交通大學醫學院附屬瑞金醫院王繼光教授、中國醫學科學院阜外醫院蔣雄京教授、巴塞爾大學醫院FelixMahfoud教授擔任上市會主席並開場致辭。
北京大學人民醫院劉健教授擔任上市會主持,另外鄭州大學第一附屬醫院韓戰營教授、青島市市立醫院賈楠教授、中國醫學科學院阜外醫院蔣雄京教授、江蘇省人民醫院孔祥清教授、新疆醫科大學第一附屬醫院馬翔教授、上海交通大學醫學院附屬瑞金醫院許建忠教授、南方醫科大學南方醫院修建成教授、蘭州大學第二醫院餘靜教授、巴塞爾大學醫院FelixMahfoud教授擔任演講嘉賓及討論小組成員。
會議直播了一例經橈動脈入路("TRA")的實時去腎神經手術演示,手術由復旦大學附屬中山醫院錢菊英教授、姚志峯教授在上市會期間成功實施且沒有出現併發症。
截至本公告發布日,Iberis®RDN系統是全球唯一獲批的可同時兼容TRA和經股動脈入路的RDN產品。TRA使RDN更安全、更有效、更便宜。公司的最終目標是將門診去腎神經手術帶給世界各地的患者。Iberis®RDN系統將由安通醫療和遠大醫藥集團有限公司("遠大醫藥")旗下心腦血管精準介入診療板塊商業主體一的凱諾威醫療科技(武漢)有限公司在中國聯合推廣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.